Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q2 2016 call → NOWe need to determine if management describes successive engagements of the same kind coming in at progressively larger size. The question asks: does management convey that the deals, orders, contracts, projects, customers, sites, or programs it is landing NOW are individually bigger, broader, or longer than the ones it was landing for the same offering not long ago, so that each new instance of essentially the same business is worth more to the company than the last? We need to look for management's own words that convey a comparison against the company's own recent past, that it's already real and recurring, and that it's early. Scan the transcript. Management discusses various businesses: Climate Control Seats (heated/ventilated), electronics, battery thermal management, Global Power, CSZ acquisition, medical, etc. Key points: - CSZ acquisition: "performing very well", "entrance into medical market", "industrial heating and cooling environmental test chambers". But does management say that the deals/orders are getting larger? They mention "we see very, very strong results" in future quarters, but not specifically about size escalation. - Battery thermal management: "launched about a year from now" (actually they say "This was launched about a year from now" - meaning it will launch about a year from now? Actually they say "This was launched about a year from now" - ambiguous. But they talk about programs coming in 2017 and 2018. No mention of increasing size. - Electronics: "first really significant outside contract" - that's a first, not necessarily escalation. - Global Power: "tremendous amount of push out" - that's shrinking, not growing. Look for any statement about deals being larger than before. The question specifically asks about "successive engagements of the same kind" coming in at progressively larger size. For example, if they say "our new contracts are bigger than our old ones" or "customers are starting at a higher level". In the transcript, there is no such statement. Management talks about growth, new opportunities, but not about the unit size of deals increasing. They mention "we see continued strength in heat vent" but that's volume. They mention "we have a historic quarter of revenue for our Global Power" but that's an accident of scheduling, not escalation.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.